Coagulation factor viia (recombinant) - Biologic Drug Details

Summary for coagulation factor viia (recombinant)

Tradenames:	1
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for coagulation factor viia (recombinant)

Recent Clinical Trials for coagulation factor viia (recombinant)

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Evergreen Therapeutics, Inc.	PHASE1
National Institutes of Health (NIH)	PHASE1
Brigham and Women's Hospital	PHASE1

See all coagulation factor viia (recombinant) clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for coagulation factor viia (recombinant) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for coagulation factor viia (recombinant) Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for coagulation factor viia (recombinant) Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Recombinant Coagulation Factor VIIa

Last updated: February 24, 2026

What is the Current Market Size and Growth Rate?

Recombinant coagulation factor VIIa (rFVIIa), marketed primarily as NovoSeven (by Novo Nordisk), targets bleeding disorders such as hemophilia A, hemophilia B, and acquired bleeding conditions. As of 2023, the global market value stands at approximately USD 2.3 billion, with a compound annual growth rate (CAGR) of 8% projected from 2023 to 2030.

The demand stems from increased prevalence of hemophilia, with an estimated 440,000 individuals worldwide. Newer indications such as intensive bleeding management in trauma and surgery expand potential use cases.

What Are the Key Market Drivers?

Primary drivers include:

• Rising Hemophilia Incidence: Over 70% of hemophilia cases remain undiagnosed globally, but diagnosed cases are increasing due to improved screening.
• Enhanced Treatment Protocols: Advances in prophylactic therapies improve patient outcomes, boosting demand for recombinant agents like rFVIIa.
• Lack of Alternatives: Recombinant factor VIIa is preferred over plasma-derived products for safety, especially due to lower risk of blood-borne pathogen transmission.
• Market Expansion in Emerging Regions: Growing healthcare infrastructure in Asia-Pacific and Latin America contributes to market growth.

What Are the Main Challenges?

• Cost and Reimbursement Issues: High treatment costs (around USD 50,000 per patient annually) limit accessibility in lower-income countries.
• Development of Biosimilars: Entry of biosimilars produces price competition, exerting downward pressure on revenues.
• Limited Indications: Predominant use in hemophilia bleeding episodes restricts broader market potential.

How Will Competitive Dynamics Evolve?

Major players include Novo Nordisk, swift developments by ilsung and BPL, and emerging biosimilar manufacturers from India and China. Expected consolidation and partnerships will likely influence market stability.

Innovations anticipated include:

• Long-acting formulations for reduced dosing frequency.
• Gene therapies that may redefine bleeding disorder management.

What Are the Revenue Projections?

Pricing assumptions vary by region, with North America and Europe contributing roughly 70% of revenues. For 2023, key financial estimates include:

Region	Revenue (USD millions)	CAGR (2023-2030)
North America	1,000	7%
Europe	700	6.5%
Asia-Pacific	300	10%
Rest of the World	300	8%

Global revenues are projected to reach USD 4.8 billion by 2030.

How Do Regulatory and Policy Environments Impact Market Trajectory?

Regulatory approvals are crucial. The FDA granted accelerated approval for novel long-acting formulations. Evolving reimbursement policies, particularly in OECD countries, continue to shape access and adoption.

In developing markets, approval timelines are longer, but price controls can influence market penetration.

What Is the Investment Outlook?

Investments focus on:

• Research & Development: To develop next-generation, long-acting, or recombinant variants with improved safety.
• Manufacturing Capacity: Scaling production to meet rising global demand, especially in emerging markets.
• Strategic Alliances: Collaborations with biotech firms to access biosimilar pathways and innovative gene therapies.

Financially, biotech companies with integrated R&D and manufacturing are positioned for growth, contingent on successful product launches and price negotiations.

Summary of Market Opportunities

• Expanding indications in trauma, surgery, and acquired bleeding.
• Biosimilar entry in cost-sensitive markets.
• Development of longer-acting formulations and gene therapies.
• Geographic expansion in underpenetrated regions.

Key Takeaways

• The recombinant coagulation factor VIIa market is growing at a CAGR of 8%, reaching USD 4.8 billion globally by 2030.
• Dominated by high-cost branded products, but biosimilar competition is on the rise.
• Growth is driven by increased hemophilia incidence, improved treatment protocols, and regional healthcare infrastructure development.
• Cost and reimbursement challenges influence market penetration, especially outside high-income economies.
• Innovation in formulations and gene therapies will reshape the market landscape over the next decade.

FAQs

1. What are the main drivers for revenue growth in recombinant factor VIIa?
   Rising hemophilia diagnoses, improved prophylactic treatments, limited alternatives, and expanding markets in emerging regions.

2. How does biosimilar competition affect the market?
   Biosimilars lead to price reductions, potentially decreasing revenue levels for branded products, especially in cost-sensitive markets.

3. What are the prospects for new formulations?
   Long-acting formulations aim to reduce dosing frequency, potentially increasing adherence and expanding market share.

4. What impact could gene therapies have on the recombinant factor VIIa market?
   Gene therapies may replace episodic treatment, reducing demand for recombinant products over time.

5. Which regions offer the most growth potential?
   Asia-Pacific and Latin America are expected to see the fastest growth, due to healthcare expansion and increasing diagnosis rates.

---

References

[1] MarketWatch. (2023). Coagulation Factor VIIa Market Size, Share & Trends.
[2] GlobalData. (2023). Hemophilia Market Outlook.
[3] World Federation of Hemophilia. (2022). Annual Global Survey.
[4] European Medicines Agency. (2023). Product Approvals for Hemophilia Treatments.
[5] IQVIA. (2023). Biopharmaceutical Market Dynamics Report.